Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Epstein

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
The American Journal of Medicine|October 31, 2006
Aldosterone blockade: an emerging strategy for abrogating progressive renal diseaseMurray Epstein
The Lancet. Diabetes & Endocrinology|October 3, 2015
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonismMurray Epstein
The Lancet. Diabetes & Endocrinology|December 4, 2014
Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney diseaseMurray Epstein
European Heart Journal|September 28, 2020
Josep Trueta and Renal Sympathetic ActivationMurray Epstein
American Journal of Nephrology|April 15, 2021
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the PresentMurray Epstein
Kidney International Reports|April 29, 2021
Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and DampersMurray Epstein
Journal of the American Society of Hypertension : JASH|April 16, 2016
The future for renal denervation depends on embracing the lessons learned from our previous studiesMurray Epstein
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|April 10, 2003
Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunctionMurray Epstein
American Journal of Hypertension|July 18, 2002
Recent landmark clinical trials: how do they modify the therapeutic paradigm?Murray Epstein
Kidney International Supplements|May 9, 2022
Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohortsMurray Epstein
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
The American Journal of Medicine|October 31, 2006
Aldosterone blockade: an emerging strategy for abrogating progressive renal diseaseMurray Epstein
The Lancet. Diabetes & Endocrinology|October 3, 2015
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonismMurray Epstein
The Lancet. Diabetes & Endocrinology|December 4, 2014
Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney diseaseMurray Epstein
European Heart Journal|September 28, 2020
Josep Trueta and Renal Sympathetic ActivationMurray Epstein
American Journal of Nephrology|April 15, 2021
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the PresentMurray Epstein
Kidney International Reports|April 29, 2021
Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and DampersMurray Epstein
Journal of the American Society of Hypertension : JASH|April 16, 2016
The future for renal denervation depends on embracing the lessons learned from our previous studiesMurray Epstein
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|April 10, 2003
Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunctionMurray Epstein
American Journal of Hypertension|July 18, 2002
Recent landmark clinical trials: how do they modify the therapeutic paradigm?Murray Epstein
Kidney International Supplements|May 9, 2022
Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohortsMurray Epstein
Pageof 8